Physician profile
Manjula Ashok
NPI 1518923309
$3,852.87
in general payments reported to CMS, 2019-2025
35 companies · $806 in 2025
The $806 reported for 2025 was more than what a typical Nephrology (Internal Medicine) provider received nationally (typical 2025 total: $311).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $570 · 2020: $371 · 2021: $725 · 2022: $323 · 2023: $448 · 2024: $608 · 2025: $806.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,863.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,863.34 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Aurinia Pharma U.S., INC. | $454.79 | 2021-2025 | Lupkynis |
| Vifor Pharma, INC. | $411.80 | 2019-2025 | Veltassa |
| Astrazeneca Pharmaceuticals LP | $373.30 | 2019-2025 | Farxiga |
| Amgen INC. | $307.67 | 2019-2025 | Krystexxa, Tavneos, Aranesp |
| Bayer Healthcare Pharmaceuticals INC. | $272.52 | 2022-2025 | |
| Opko Pharmaceuticals, LLC | $246.32 | 2019-2025 | Rayaldee |
| Fresenius USA Marketing, INC. | $215.39 | 2019-2022 | |
| Otsuka America Pharmaceutical, INC. | $175.06 | 2019-2025 | Jynarque |
| Novo Nordisk INC | $158.41 | 2022-2025 | Ozempic, Wegovy |
| Glaxosmithkline, LLC. | $150.06 | 2021-2025 | Benlysta, Jesduvroq, Arexvy |
| Arbor Pharmaceuticals, INC. | $134.97 | 2019-2021 | |
| Daiichi Sankyo INC. | $121.71 | 2019-2023 | Injectafer |
| Ardelyx, INC. | $87.43 | 2024-2025 | Ibsrela |
| Mallinckrodt Hospital Products INC. | $86.91 | 2021-2024 | Terlivaz, Acthar |
| Horizon Therapeutics Plc | $86.33 | 2019-2022 |
Show all 35 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Manjula Ashok listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.